1053 / 1851
Keynote-024:
Pembrolizumab vs Chemotherapy as first line therapy in stage IV NSCLC
Reck M. et al. NEJM 2016
Phase III trial
Pembrolizumab vs Platinum based doublet
305 patients enrolled
All patients had a
PD-L1 expression on
at least 50% of the tumor cells